

DAFTAR PUSTAKA

- Abu-Farha, M., et al, 2020. Impact of diabetes in patients diagnosed with COVID-19, **Frontiers in Immunology**. : 11(December): pp-1-11.
- Alkundi, A., et al, 2020. Clinical characteristics and outcomes of COVID-19 hospitalized patients with diabetes in the United Kingdom: a retrospective single centre study, **Diabetes Research and Clinical Practice Journal**. :165: pp-1-7.
- American Diabetes Association, 2020. Standards of medical care in diabetes-2020, **Diabetes Care**. :43: pp-S1-S212.
- American Pharmacists Association, 2016. **Drug Information Handbook with International Trade Name Index**, 25th edition, USA: Lexicomp, pp-963-1312.
- Bhatraju, P. K., et al, 2020. COVID-19 in critically ill patients in the Seattle region — case series, **New England Journal of Medicine**. :382(21): pp. 2012-2022.
- Bode, B., et al, 2020. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States, **Journal of Diabetes Science and Technology**. :14(4): pp-813-821.
- Bornstein, S. R., et al, 2020. Practical recommendations for the management of diabetes in patients with COVID-19, **The Lancet Diabetes and Endocrinology**. :8(6): pp-546-550.
- Burhan, E., et al. 2020. Pedoman Tatalaksana COVID-19, Edisi ke-2, Jakarta: Perhimpunan Dokter Paru Indonesia, pp-1-101.
- Chan, Y. J., et al, 2020. Association between body mass index and risk of COVID-19 : a nationwide case-control study in South Korea, **Clinical Infection Disease**. :71: pp-1-18.
- Chen, X., et al, 2020. Hypertension and diabetes delay the viral clearance in COVID-19 patients, **MedRxiv**. : pp-1-12.
- Chen, Y., et al, 2020. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis, **MedRxiv**. : pp-1-12.
- Chee, Y. J., Tan, S. K. and Yeoh, E., 2020. Dissecting the interaction between COVID-19 and diabetes mellitus, **Journal of Diabetes Investigation**. :11(5): pp-1104-1114.

- Chen, N., et al, 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, **The Lancet.**: 395(10223): pp-507-513.
- Chen, Y., et al, 2020. Clinical Characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication, **Diabetes Care.**: 43(7): pp-1399-1407.
- Chow, N., et al, 2020. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 — United States, February 12–March 28, 2020, **Morbidity and Mortality Weekly Report.**: 69(13): pp-382-386.
- Corrao, S., et al, 2021. Type 2 diabetes mellitus and COVID-19: a narrative review, **Frontiers in Endocrinology.**: 12(March): pp-1-10.
- Crouse, A. B., et al, 2021. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes, **Frontiers in Endocrinology.**: 11(January): pp-1-8.
- De Wit, E., et al, 2020. SARS and MERS: recent insights into emerging coronaviruses, **Nature Reviews Microbiology.**: 14(8): pp-523-534.
- Diniz Vilela, D., et al, 2016. The role of metformin in controlling oxidative stress in muscle of diabetic rats, **Oxidative Medicine and Cellular Longevity.**: 2016: pp-1-9.
- Dixon, E. A. and Peters, U., 2018. The effect of obesity on lung function, **Expert Rev. Respir. Med.**:12(9): pp-755-767.
- Fernandez, C., et al, 2020. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality, **Journal of Internal Medicine.**: 284(4): pp-377-387.
- Gorricho, J., et al, 2020. Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case–control study, **British Journal of Clinical Pharmacology.**: 83(9): pp-2034-2044.
- Guan, W., et al, 2020. Clinical characteristics of coronavirus disease 2019 in China, **New England Journal of Medicine.**: 382(18): pp-1708-1720.
- Guozhen Li, et al, 2020. Clinical characteristics of diabetic patients with diabetic retinopathy, **Journal of Diabetes Research.**: 2020: pp-1-5.
- Hodgson, K., et al, 2015. Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections, **Immunology.**: 144(2): pp-171-185.

- Hoffmann, M., et al, 2020. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells, **Cell.**: 181(2): pp-271-280.
- Huang, C., et al, 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, **The Lancet.**: 395(10223): pp.-497-506.
- Hussain, A., et al, 2020. COVID-19 and diabetes: knowledge in progress, **Diabetes Research and Clinical Practice.**: 162: pp-1-9.
- Jayanama, K., et al, 2021. The association between body mass index and severity of coronavirus disease 2019 (COVID-19): a cohort study, **PLoS ONE.**:16(February): pp-1-10.
- Jin, J. M., et al, 2020. Gender differences in patients with COVID-19: focus on severity and mortality, **Frontiers in Public Health.**: 8(152): pp-1-6.
- Karyono, D. R., et al, 2020. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia, **Journal of Community Empowerment for Health.**: 3(2): pp-77-84.
- Katsiki, N. and Ferrannini, E., 2020. Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?, **Journal of Diabetes and its Complications.**: 34(12): pp-1-8.
- Kementerian Kesehatan Republik Indonesia, 2020. keputusan menteri kesehatan Republik Indonesia nomor HK.01.07/MenKes/413/2020 tentang pedoman pencegahan dan pengendalian corona virus disease 2019 (COVID-19), pp-1-207.
- Kimura, T. and Namkoong, H., 2020. Susceptibility of the obese population to COVID-19, **International Journal of Infectious Diseases.**: 101: pp-380-381.
- Koliaki, C., et al, 2020. Clinical management of diabetes mellitus in the era of COVID-19: practical issues, peculiarities and concerns, **Journal of Clinical Medicine.**: 9(7): pp-1-25.
- Kulcsar, K. A., et al, 2020. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection, **JCI Insight.**: 4(20): pp-1-18.
- Li, G., et al, 2020. Coronavirus infections and immune responses, **Journal of Medical Virology.**: 92(4): pp-424-432.
- Li, X., et al, 2020. Molecular immune pathogenesis and diagnosis of COVID-19, **Journal of Pharmaceutical Analysis.**: 10(2): pp-102-108.

- Li, Y., et al, 2020. Asymptomatic and symptomatic patients with non-severe coronavirus disease (COVID-19) have similar clinical features and virological courses: a retrospective single center study, **Frontiers in Microbiology**.: 11(June): pp-1-8.
- Lim, S., et al, 2021. COVID-19 and diabetes mellitus: from pathophysiology to clinical management, **Nature Reviews Endocrinology**.: 17: pp-11-30.
- Liu, Y., et al, 2020. The reproductive number of COVID-19 is higher compared to SARS coronavirus, **Journal of Travel Medicine**.: 27(2): pp-1-4.
- Liu, R. and Nikolajczyk, B. S., 2019. Tissue immune cells fuel obesity-associated inflammation in adipose tissue and beyond, **Frontiers in Immunology**.: 10(1587): pp-1-16.
- Longo, M., et al, 2020. Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies, **Cardiovascular Diabetology**.: 19(1): pp-1-5.
- Maddaloni., et al, 2020. COVID-19 and diabetes mellitus: unveiling the interaction of two pandemics, **Diabetes Metabolism Research and Reviews**.: 36(7): pp-19-20.
- Mcmurray, J. J. V., et al, 2020. Special report renin – angiotensin – aldosterone system inhibitors in patients with COVID-19, **New England Journal of Medicine**.: 382: pp-1653-1659.
- Mittal, A., et al, 2020. COVID-19 pandemic: insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2, **PLOS pathogens**.: 16(8): pp-1-19.
- Muniyappa, R. and Gubbi, S., 2020. COVID-19 pandemic, coronaviruses, and diabetes mellitus, **American Journal of Physiology - Endocrinology and Metabolism**.: 318: pp-E736-E741.
- Onder, G. et al. (2020) ‘Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy’, *JAMA - Journal of the American Medical Association*, 323(18), pp. 1775–1776.
- Perkumpulan Endokrinologi Indonesia, 2019. **Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2019**. Jakarta: PB PERKENI, pp-1-118.
- Qin, C., et al, 2020, Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China, **Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America**.: 71(15): pp-762-768.

- Raimondi, F., et al, 2021. Covid-19 and gender: lower rate but same mortality of severe disease in women—an observational study, **BMC Pulmonary Medicine**.: 21(1): pp-1-11.
- Rao, S., et al. 2020. Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: a mendelian randomization analysis highlights tentative relevance of diabetes-related traits, **Diabetes Care**.: 43(7): pp-1416-1426.
- Richardson, S., et al, 2020. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, **Journal of the American Medical Association**.: 323(20): pp-2052-2059.
- Roca-Ho, H., et al, 2017. Characterization of ACE and ACE2 expression within different organs of the NOD mouse, **International Journal of Molecular Sciences**, 18(3): pp- 1-13.
- Romaní-Pérez, M., et al, 2015. Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats, **Endocrinology**.: 156(10): pp-3559-3569.
- Satuan Tugas Penanganan COVID-19 (2021) Peta Sebaran COVID-19. Available at: <https://covid19.go.id/peta-sebaran-covid19> (Accessed: 18 May 2021).
- Schwartz, S. S., et al, 2016. The time is right for a new classification system for diabetes: rationale and implications of the β -cell-centric classification schema, **Diabetes Care**.: 39(2): pp-179-186.
- Singh, A. K., et al, 2020. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations, **Diabetes and Metabolic Syndrome: Clinical Research and Reviews**.: 14(4): pp-303-310.
- Singh, A. K., et al, 2020. Comorbidities in COVID-19: outcomes in hypertensive cohort and controversies with renin angiotensin system blockers, **Diabetes and Metabolic Syndrome: Clinical Research and Reviews**.: 14(4): pp-283-287.
- Singh, A. K. and Singh, R., 2020. Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?, **Diabetes Research and Clinical Practice Journal**.: 165: pp-1-4.
- Susilo, A., et al, 2020. Coronavirus disease 2019: tinjauan literatur terkini, **Jurnal Penyakit Dalam Indonesia**.: 7(1): pp-45-67.

- Ueyama, H., et al, 2020. Gender difference is associated with severity of coronavirus disease 2019 infection: an insight from a meta-analysis, **Critical Care Explorations.**: 2: pp-1-5.
- Ugwueze, C. V., et al, 2020. COVID-19 and diabetes mellitus: the link and clinical implications, **Dubai Diabetes and Endocrinology Journal.**: 26: pp-69-77.
- Urra, J. M., et al, 2020. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients, **Clinical Immunology.**: 217: pp-1-6.
- Wang, D., et al, 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, **Journal of the American Medical Association.**: 323(11): pp-1061-1069.
- Wiersinga, W. J., et al, 2020. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review, **Journal of the American Medical Association.**: 324(8): pp-782-793.
- World Health Organization, 2020. Clinical management of COVID-19: interim guidance, pp. 1-81.
- Wu, C., et al, 2020. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, **JAMA Internal Medicine.**: 180(7): pp-934-943.
- Wu, C., et al, 2020. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV, in the nasal tissue, **MedRxiv.** : pp-1-6.
- Wu, S., et al, 2020. Understanding factors influencing the length of hospital stay among non-severe COVID-19 patients: a retrospective cohort study in a Fangcang shelter hospital, **PLOS ONE.**: 15: pp-1-14.
- Wu, Z., & McGoogan, J. M., 2020. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention, **Journal of the American Medical Association.**: 323(13): pp-1239-1242.
- Xu, Z., et al, 2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome, **The Lancet Respiratory Medicine.**: 8(4): pp-420-422.
- Yang, X., et al, 2020. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, **The Lancet Respiratory Medicine.**: 8(5): pp-475-481.

- Yuki, K., Fujiogi, M., & Koutsogiannaki, S., 2020. COVID-19 pathophysiology: a review, **Clinical Immunology.**: 215: pp-1-8.
- Zainuddin, M., 2014. **Metodologi Penelitian Kefarmasian dan Kesehatan**, Surabaya: Airlangga University Press, pp. 1-139.
- Zhang, W., et al, 2014. Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis, **The Scientific World Journal.**: 2014: pp-1-7.
- Zhou, P., et al, 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin, **Nature.**: 579: pp-270-273.
- Zhu, L., et al, 2020. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes, **Cell Metabolism.**: 31(6): pp-1068-1077.
- Zumla, A., et al, 2020. Reducing mortality from 2019-nCoV: host-directed therapies should be an option, **The Lancet.**: 395(10224): pp-e35-e36.